Cellectar Biosciences is partnering with Florida Cancer Specialists & Research Institute (FCS) to advance patient care and further define the U.S. treatment landscape, the company announced today. According to a…
Cellectar Biosciences has started a trial for CLR 131 in Waldenstrom’s macroglobulinemia (WM), the company announced recently. According to a release, the trial will include 50 WM patients who will…
Cellectar Biosciences announced today that it has received a European patent for the composition of matter and use protection for the treatment and/or diagnosis of cancer and cancer stem cells for…
Cellectar Biosciences has received a patent for CLR 131 by the Japan Patent Office, the company announced recently. “Certain cancers such as pediatric lymphomas and leukemias have a higher prevalence…
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent (No. P150207US03) that covers a method of use for CLR 131 in multiple myeloma, the company announced today….
Cellectar Biosciences has extended its collaboration with Pierre Fabre, a French pharmaceutical company, the company announced today. “The extension of our research agreement with Pierre Fabre allows us to further…
Cellectar Biosciences announced today it has entered into a strategic collaboration with Onconova Therapeutics, a biopharmaceutical company, to develop new phospholipid drug conjugates (PDC). According to a release, the Newtown,…
Cellectar Biosciences‘ Phospholipid Drug Conjugate (PDC) research program has generated numerous PDC molecules that show “significant” improved pharmacologic activity, the company announced today. According to a release, Cellectar’s research demonstrates that…
Cellectar Biosciences’ CLR 131 has achieved an overall survival of greater than 22 months in advanced multiple myeloma patients, the company announced today. “We continue to make meaningful progress on…
Cellectar Biosciences announced today that it will collaborate with Avicenna Oncology, a clinical stage biotechnology company based in Switzerland, to develop new phospholipid drug conjugates for solid tumors. According to…
